336 related articles for article (PubMed ID: 15623649)
1. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
Horiguchi A; Sumitomo M; Asakuma J; Asano T; Asano T; Hayakawa M
Clin Cancer Res; 2004 Dec; 10(24):8648-55. PubMed ID: 15623649
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors.
Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Nakamura H
Cancer Res; 2001 Jun; 61(12):4885-91. PubMed ID: 11406567
[TBL] [Abstract][Full Text] [Related]
3. Stimulatory effects of low-dose 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on hepatocyte growth factor-induced angiogenesis: involvement of p38 mitogen-activated protein kinase.
Uruno A; Sugawara A; Kudo M; Satoh F; Saito A; Ito S
Hypertens Res; 2008 Nov; 31(11):2085-96. PubMed ID: 19098381
[TBL] [Abstract][Full Text] [Related]
4. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
Woodard J; Sassano A; Hay N; Platanias LC
Clin Cancer Res; 2008 Jul; 14(14):4640-9. PubMed ID: 18628479
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells.
Horiguchi A; Asano T; Asano T; Ito K; Sumitomo M; Hayakawa M
J Urol; 2008 Aug; 180(2):729-36. PubMed ID: 18555493
[TBL] [Abstract][Full Text] [Related]
6. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho.
Kusama T; Mukai M; Tatsuta M; Nakamura H; Inoue M
Int J Oncol; 2006 Jul; 29(1):217-23. PubMed ID: 16773203
[TBL] [Abstract][Full Text] [Related]
8. Effect of a matrix metalloproteinase inhibitor (ONO-4817) on lung metastasis of murine renal cell carcinoma.
Muraishi Y; Mitani N; Fuse H; Saiki I
Anticancer Res; 2001; 21(6A):3845-52. PubMed ID: 11911256
[TBL] [Abstract][Full Text] [Related]
9. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Sivaprasad U; Abbas T; Dutta A
Mol Cancer Ther; 2006 Sep; 5(9):2310-6. PubMed ID: 16985065
[TBL] [Abstract][Full Text] [Related]
10. A disconnect between antitumor and antiangiogenic effects of fluvastatin in vitro and in vivo.
Klement H; Rak J
Neoplasma; 2006; 53(2):111-8. PubMed ID: 16575466
[TBL] [Abstract][Full Text] [Related]
11. Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression.
Ferri N; Granata A; Pirola C; Torti F; Pfister PJ; Dorent R; Corsini A
Mol Pharmacol; 2008 Jul; 74(1):144-53. PubMed ID: 18413661
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of differentiation/DNA binding proteins Id1 and Id3 are regulated by statins in endothelial cells.
Pammer J; Reinisch C; Kaun C; Tschachler E; Wojta J
Endothelium; 2004; 11(3-4):175-80. PubMed ID: 15370294
[TBL] [Abstract][Full Text] [Related]
13. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Inoue M; Nakamura H
Gastroenterology; 2002 Feb; 122(2):308-17. PubMed ID: 11832446
[TBL] [Abstract][Full Text] [Related]
14. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation.
Azuma RW; Suzuki J; Ogawa M; Futamatsu H; Koga N; Onai Y; Kosuge H; Isobe M
Cardiovasc Res; 2004 Dec; 64(3):412-20. PubMed ID: 15537494
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
Inamoto T; Yamochi T; Ohnuma K; Iwata S; Kina S; Inamoto S; Tachibana M; Katsuoka Y; Dang NH; Morimoto C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3470-7. PubMed ID: 16740772
[TBL] [Abstract][Full Text] [Related]
16. Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity.
Duncan RE; Lau D; El-Sohemy A; Archer MC
Biochem Pharmacol; 2004 Nov; 68(9):1739-47. PubMed ID: 15450939
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle arrest and apoptotic induction in LNCaP cells by MCS-C2, novel cyclin-dependent kinase inhibitor, through p53/p21WAF1/CIP1 pathway.
Park HY; Kim MK; Moon SI; Cho YH; Lee CH
Cancer Sci; 2006 May; 97(5):430-6. PubMed ID: 16630142
[TBL] [Abstract][Full Text] [Related]
18. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
Huynh H; Nguyen TH; Panasci L; Do P
Cancer; 2004 Dec; 101(12):2881-91. PubMed ID: 15529313
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
Gao J; Jia WD; Li JS; Wang W; Xu GL; Ma JL; Ge YS; Yu JH; Ren WH; Liu WB; Zhang CH
J Int Med Res; 2010; 38(4):1413-27. PubMed ID: 20926014
[TBL] [Abstract][Full Text] [Related]
20. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
